Protara Therapeutics, Inc.
TARA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001359931
No open-market purchases or sales by Protara Therapeutics, Inc. insiders were filed in the last 90 days; 119 institutions reported holding it in 13F filings for Q2 2026, worth $176.0M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Protara Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 35 | 33 | −2 |
| Shares | 6.50M | 5.93M | −568.4K (−8.7%) |
| Value | $33.2M | $18.4M | −$14.8M (−44.6%) |
New holders (3)
Institutions that held Protara Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 10,103 | $30.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 1,807 | $5.00K | 0.00% |
| JPMorgan Chase & Co | 352 | $1.00K | 0.00% |
Sold out (5)
Institutions that held Protara Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Goldman Sachs Group Inc | 152,847 | $781.0K |
| Trexquant Investment LP | 16,313 | $83.0K |
| Prelude Capital Management, LLC | 12,872 | $66.0K |
| Barclays PLC | 2,510 | $13.0K |
| Bank of America Corp | 745 | $3.00K |